Drugs / Ad26.Mos4.HIV
Trials 8 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 13 trials | ||||||
| Phase 1 | NCT06205056 | Jan 2024 → Dec 2025 overdue | HIV infectious disease | U.S. Army Medical Research and Development Command | Recruiting | No outcome recorded |
| Phase 1 | NCT05769569 | Sep 2023 → Jul 2025 | HIV infectious disease | Henry M. Jackson Foundation for the Advancement of Military Medicine | Withdrawn | No outcome recorded |
| Phase 1 | NCT03307915 | Mar 2018 → Nov 2021 | HIV infectious disease | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/23 trials | ||||||
| Phase 1/2 | NCT04983030 | Apr 2022 → Feb 2026 | AIDS, acquired immunodeficiency | Boris Juelg, MD PhD | Completed | No outcome recorded |
| Phase 1/2 | NCT02935686 | Mar 2017 → Nov 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 1/2 | NCT02788045 | Jul 2016 → Apr 2022 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT03060629 | Nov 2017 → Feb 2022 | — | Janssen Vaccines & Prevention B.V. | Terminated | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT03964415 | Oct 2019 → Aug 2023 | — | Janssen Vaccines & Prevention B.V. | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 8 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Ad26.Mos4.HIV | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02935686 ↗ |
| Modality | Vaccine | “Ad26 vectored vaccine” NCT02788045 ↗ |
| Route | Intramuscular | “administered intramuscularly” NCT02788045 ↗ |